Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02559154 | Modified Bortezomib-based Combination Therapy for Multiple Myeloma | unknown | Phase 4 | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT03513601 | Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT01819792 | Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia(LAMVIRE) | completed | Phase 4 | 119 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01906671 | Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid | unknown | Phase 4 | 16 | Kjeld SchmiegelowOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00854581 | Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma | terminated | Phase 4 | 13 | University of MiamiOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | terminated | Phase 4 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT00211211 | FREE Study - Fracture Reduction Evaluation | completed | Phase 4 | 300 | Medtronic Spine LLCINDUSTRY | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01347996 | Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia | completed | Phase 4 | 84 | Cytovia, Inc.OTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01746992 | CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma | unknown | Phase 4 | 200 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00666978 | Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking | completed | Phase 4 | 540 | Lisa Sanderson Cox, PhDOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT03332511 | Efficacy and Safety of Nilotinib in CML-CP(ENESTKorea) | completed | Phase 4 | 110 | Seoul National University HospitalOTHER | 0 | Nov 6, 2017 | clinicaltrials |
| NCT00430352 | MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. | completed | Phase 4 | 545 | Hoffmann-La RocheINDUSTRY | 24 | Aug 14, 2017 | clinicaltrials |
| NCT01569724 | Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma(TgBEX) | completed | Phase 4 | 10 | Rennes University HospitalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT03216070 | Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia | unknown | Phase 4 | 12 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00576472 | Learning Impairments Among Survivors of Childhood Cancer | completed | Phase 4 | 469 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT03150134 | Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients | unknown | Phase 4 | 100 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT03150602 | A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy | unknown | Phase 4 | 22 | Taiwan Mundipharma Pharmaceuticals Ltd.INDUSTRY | 1 | May 12, 2017 | clinicaltrials |
| NCT01625455 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome | terminated | Phase 4 | 7 | Vanderbilt University Medical CenterOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01605981 | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.(MACS1881) | withdrawn | Phase 4 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00686543 | Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) | completed | Phase 4 | 75 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT02086487 | Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy(NISRI) | terminated | Phase 4 | 98 | King Abdullah International Medical Research CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01206088 | Tasigna in Glivec-resistant or Intolerant Patients in CML | completed | Phase 4 | 93 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00171899 | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) | completed | Phase 4 | 80 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00786812 | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(MACS0439) | completed | Phase 4 | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01410929 | Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma(MM) | withdrawn | Phase 4 | 0 | DFINE Inc.INDUSTRY | 0 | Jan 20, 2017 | clinicaltrials |
| NCT03026842 | Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) | unknown | Phase 4 | 180 | The First Hospital of Jilin UniversityOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT03010579 | Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation | unknown | Phase 4 | 70 | Peking UniversityOTHER | 1 | Jan 5, 2017 | clinicaltrials |
| NCT02487316 | A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | withdrawn | Phase 4 | 0 | Jun ZhuOTHER | 1 | Dec 30, 2016 | clinicaltrials |
| NCT02585947 | To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma | unknown | Phase 4 | 90 | Seoul National University HospitalOTHER | 1 | Dec 21, 2016 | clinicaltrials |
| NCT02996617 | PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia | unknown | Phase 4 | 240 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
| NCT02992834 | Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma | unknown | Phase 4 | 10 | jiangjingtingOTHER | 1 | Dec 14, 2016 | clinicaltrials |
| NCT01841814 | Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy(LYMPHOS) | withdrawn | Phase 4 | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
| NCT02782845 | An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 4 | 53 | Hoffmann-La RocheINDUSTRY | 2 | Nov 21, 2016 | clinicaltrials |
| NCT01368523 | Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial | completed | Phase 4 | 19 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 16, 2016 | clinicaltrials |
| NCT02953730 | The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents | completed | Phase 4 | 9 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 3, 2016 | clinicaltrials |
| NCT02938741 | ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors | unknown | Phase 4 | 130 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02929615 | Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors | unknown | Phase 4 | 50 | Peking UniversityOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT00845221 | Glivec in Pediatric Chronic Myeloid Leukemia (CML) | completed | Phase 4 | 44 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT01664975 | Treatment of Peripheral T-cell Lymphoma | completed | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT02894645 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | unknown | Phase 4 | 500 | National University Hospital, SingaporeOTHER | 2 | Sep 30, 2016 | clinicaltrials |
| NCT02027064 | Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT | unknown | Phase 4 | 40 | Peking University People's HospitalOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT02905916 | The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy | unknown | Phase 4 | 217 | Peking UniversityOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT02905942 | PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation | unknown | Phase 4 | 96 | Peking UniversityOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01297777 | Imatinib in KIT-negative Systemic Mastocytosis | completed | Phase 4 | 10 | Hospital Virgen de la SaludOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT02880709 | The Effect of Special Diets in Hematological Cancer Patients | completed | Phase 4 | 32 | Jens Rikardt AndersenOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT02268890 | A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma | completed | Phase 4 | 18 | Johnson & Johnson Taiwan LtdINDUSTRY | 1 | Jul 11, 2016 | clinicaltrials |
| NCT02805218 | PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy | completed | Phase 4 | 410 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 20, 2016 | clinicaltrials |
| NCT02784561 | Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | unknown | Phase 4 | 80 | Chinese PLA General HospitalOTHER | 0 | May 27, 2016 | clinicaltrials |
Data updated 23 days agoSource updated May 4, 2018source: clinicaltrials